Literature DB >> 26116806

Effects of the Learning Curve on Efficacy of Radiofrequency Ablation for Barrett's Esophagus.

Sarina Pasricha1, Cary Cotton1, Kelly E Hathorn1, Nan Li1, William J Bulsiewicz1, W Asher Wolf1, V Raman Muthusamy2, Srinadh Komanduri3, Herbert C Wolfsen4, Ron E Pruitt5, Atilla Ertan6, Gary W Chmielewski7, Nicholas J Shaheen8.   

Abstract

BACKGROUND & AIMS: Complete eradication of Barrett's esophagus (BE) often requires multiple sessions of radiofrequency ablation (RFA). Little is known about the effects of case volume on the safety and efficacy of RFA or about the presence or contour of learning curves for this procedure.
METHODS: We collected data from the US RFA Patient Registry (from 148 institutions) for patients who underwent RFA for BE from July 2007 to July 2011. We analyzed the effects of the number of patients treated by individual endoscopists and individual centers on safety and efficacy outcomes of RFA. Outcomes, including stricture, bleeding, hospitalization, and complete eradication of intestinal metaplasia (CEIM), were assessed using logistic regression. The effects of center and investigator experience on numbers of treatment sessions to achieve CEIM were examined using linear regression.
RESULTS: After we controlled for potential confounders, we found that as the experience of endoscopists and centers increased with cases, the numbers of treatment sessions required to achieve CEIM decreased. This relationship persisted after adjusting for patient age, sex, race, length of BE, and presence of pretreatment dysplasia (P < .01). Center experience was not significantly associated with overall rates of CEIM or complete eradication of dysplasia. We did not observe any learning curve with regard to risks of stricture, gastrointestinal bleeding, perforation, or hospitalization (P > .05).
CONCLUSIONS: Based on analysis of a large multicenter registry, efficiency of the treatment, as measured by number of sessions needed to achieve CEIM, increased with case volume, indicating a learning curve effect. This trend began to disappear after treatment of approximately 30 patients by the center or individual endoscopist. However, there was no significant association between safety or efficacy outcomes and previous case volume.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer Prevention; Database Analysis; Endoscopy; Training

Mesh:

Year:  2015        PMID: 26116806      PMCID: PMC4584171          DOI: 10.1053/j.gastro.2015.06.012

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

1.  Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus.

Authors:  Prateek Sharma; Gary W Falk; Allan P Weston; Dean Reker; Mark Johnston; Richard E Sampliner
Journal:  Clin Gastroenterol Hepatol       Date:  2006-04-17       Impact factor: 11.382

2.  The learning curve for EMR with circumferential mucosal incision in treating intramucosal gastric neoplasm.

Authors:  Il Ju Choi; Chan Gyoo Kim; Hee Jin Chang; Sang Gyun Kim; Myeong-Cherl Kook; Jae-Moon Bae
Journal:  Gastrointest Endosc       Date:  2005-12       Impact factor: 9.427

3.  Prevalence of Barrett's esophagus in the general population: an endoscopic study.

Authors:  Jukka Ronkainen; Pertti Aro; Tom Storskrubb; Sven-Erik Johansson; Tore Lind; Elisabeth Bolling-Sternevald; Michael Vieth; Manfred Stolte; Nicholas J Talley; Lars Agréus
Journal:  Gastroenterology       Date:  2005-12       Impact factor: 22.682

Review 4.  Clinical practice. Barrett's esophagus.

Authors:  Prateek Sharma
Journal:  N Engl J Med       Date:  2009-12-24       Impact factor: 91.245

5.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus.

Authors:  B J Reid; R C Haggitt; C E Rubin; G Roth; C M Surawicz; G Van Belle; K Lewin; W M Weinstein; D A Antonioli; H Goldman
Journal:  Hum Pathol       Date:  1988-02       Impact factor: 3.466

6.  Increasing incidence of Barrett's oesophagus in the general population.

Authors:  E M van Soest; J P Dieleman; P D Siersema; M C J M Sturkenboom; E J Kuipers
Journal:  Gut       Date:  2005-04-27       Impact factor: 23.059

7.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.

Authors:  E Montgomery; M P Bronner; J R Goldblum; J K Greenson; M M Haber; J Hart; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; A Y Toledano; Y Shyr; K Washington
Journal:  Hum Pathol       Date:  2001-04       Impact factor: 3.466

8.  Factors affecting complete resection of gastric tumors by the endoscopic mucosal resection procedure.

Authors:  Takanori Ohyama; Yasuki Kobayashi; Katsumi Mori; Katsumi Kano; Yukihiro Sakurai; Yuzuru Sato
Journal:  J Gastroenterol Hepatol       Date:  2002-08       Impact factor: 4.029

Review 9.  Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis.

Authors:  Marjolein Sikkema; Pieter J F de Jonge; Ewout W Steyerberg; Ernst J Kuipers
Journal:  Clin Gastroenterol Hepatol       Date:  2009-10-20       Impact factor: 11.382

10.  Radiofrequency ablation in Barrett's esophagus with dysplasia.

Authors:  Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

View more
  6 in total

Review 1.  Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium.

Authors:  Sachin Wani; V Raman Muthusamy; Nicholas J Shaheen; Rena Yadlapati; Robert Wilson; Julian A Abrams; Jacques Bergman; Amitabh Chak; Kenneth Chang; Ananya Das; John Dumot; Steven A Edmundowicz; Glenn Eisen; Gary W Falk; M Brian Fennerty; Lauren Gerson; Gregory G Ginsberg; David Grande; Matt Hall; Ben Harnke; John Inadomi; Janusz Jankowski; Charles J Lightdale; Jitin Makker; Robert D Odze; Oliver Pech; Richard E Sampliner; Stuart Spechler; George Triadafilopoulos; Michael B Wallace; Kenneth Wang; Irving Waxman; Srinadh Komanduri
Journal:  Am J Gastroenterol       Date:  2017-06-01       Impact factor: 10.864

2.  Endoscopic Eradication Therapy in Barrett's Esophagus.

Authors:  Swathi Eluri; Nicholas J Shaheen
Journal:  Tech Gastrointest Endosc       Date:  2017-06-12

Review 3.  Mucosal Ablation in Patients with Barrett's Esophagus: Fry or Freeze?

Authors:  Kavel Visrodia; Liam Zakko; Kenneth K Wang
Journal:  Dig Dis Sci       Date:  2018-08       Impact factor: 3.199

4.  Quality indicators for Barrett's endotherapy (QBET): UK consensus statements for patients undergoing endoscopic therapy for Barrett's neoplasia.

Authors:  Durayd Alzoubaidi; Krish Ragunath; Sachin Wani; Ian D Penman; Nigel John Trudgill; Marnix Jansen; Matthew Banks; Pradeep Bhandari; Allan John Morris; Robert Willert; Phil Boger; Howard L Smart; Narayanasamy Ravi; Jason Dunn; Charles Gordon; Jayan Mannath; Inder Mainie; Massi di Pietro; Andrew M Veitch; Sally Thorpe; Cormac Magee; Martin Everson; Sarmed Sami; Paul Bassett; David Graham; Stephen Attwood; Oliver Pech; Prateek Sharma; Laurence B Lovat; Rehan Haidry
Journal:  Frontline Gastroenterol       Date:  2019-08-14

5.  Complication rates of trainee- versus attending-performed upper gastrointestinal endoscopy.

Authors:  David I Fudman; Kenneth R Falchuk; Joseph D Feuerstein
Journal:  Ann Gastroenterol       Date:  2019-03-28

Review 6.  Management of Barrett's esophagus with dysplasia refractory to radiofrequency ablation.

Authors:  Kara L Raphael; Arvind J Trindade
Journal:  World J Gastroenterol       Date:  2020-05-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.